research Oral minoxidil bio‐activation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern hair loss
Minoxidil activation by hair enzymes predicts treatment success for female hair loss.
Search
for
Sort by
Research
990-1000 / 1000+ results 
research The application of optical technology in the diagnosis and therapy of oxidative stress-mediated hepatic ischemia-reperfusion injury
Optical imaging and light therapy show promise for diagnosing and treating liver injury caused by surgery.
research Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria
Pegvaliase is recommended for treating adults with phenylketonuria.
research LB1040 Machine learning-based predictive model with routine blood work identifies moderate-severe alopecia areata
Machine learning can use blood tests to help predict moderate-to-severe alopecia areata.
research Hereditary Mucoepithelial Dysplasia and Autosomal-Dominant IFAP Syndrome Is a Clinical Spectrum Due to SREBF1 Variants
A mutation in the SREBF1 gene causes both hereditary mucoepithelial dysplasia and IFAP syndrome, which are related conditions.
research The Belgian Ten‐Center Open Label Trial of Topical 2% Minoxidil Solution in Early Male Pattern Alopecia
Minoxidil is safe and effective for treating early male pattern baldness.
research LB1101 Evaluating the cardiovascular safety of low-dose oral minoxidil in patients with non-scarring alopecia: A retrospective cohort study
Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.
research MicroRNA 조절을 통한 상처 치유 기전에 관한 연구
MIR135b affects wound healing by targeting genes, and PDRN may help heal wounds by altering this pathway.
research In Vivo Confocal Microscopy for Automated Detection of Meibomian Gland Dysfunction: A Study Based on Deep Convolutional Neural Networks
research Additional Benefit Scoring During Health Technology Assessment in Germany - Its Drivers and Impact on Pricing and Discount for Orphan Drugs
Orphan drug benefit scores in Germany are influenced by phase III data and lack of alternatives, but not linked to price or discounts.